Pike-Overzet K - Search Results

1

Preclinical Development of Autologous Hematopoietic Stem Cell-Based Gene Therapy for Immune Deficiencies: A Journey from Mouse Cage to Bed Side.

Garcia-Perez L, Ordas A, Canté-Barrett K, Meij P, Pike-Overzet K, Lankester A, Staal FJT. Garcia-Perez L, et al. Pharmaceutics. 2020 Jun 13;12(6):549. doi: 10.3390/pharmaceutics12060549. Pharmaceutics. 2020. PMID: 32545727 Free PMC article. Review.

2

New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, Baert MR, van der Spek P, Koster EE, Reinders MJ, van Dongen JJ, Langerak AW, Staal FJ. Dik WA, et al. J Exp Med. 2005 Jun 6;201(11):1715-23. doi: 10.1084/jem.20042524. Epub 2005 May 31. J Exp Med. 2005. PMID: 15928199 Free PMC article.

3

T-sing progenitors to commit.

Weerkamp F, Pike-Overzet K, Staal FJ. Weerkamp F, et al. Trends Immunol. 2006 Mar;27(3):125-31. doi: 10.1016/j.it.2006.01.006. Epub 2006 Feb 10. Trends Immunol. 2006. PMID: 16473042 Review.

4

Gene therapy: is IL2RG oncogenic in T-cell development?

Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH, Howe SJ, Reinders MJ, Thrasher AJ, Wagemaker G, van Dongen JJ, Staal FJ. Pike-Overzet K, et al. Nature. 2006 Sep 21;443(7109):E5; discussion E6-7. doi: 10.1038/nature05218. Nature. 2006. PMID: 16988660

5

T-, B- and NK-lymphoid, but not myeloid cells arise from human CD34(+)CD38(-)CD7(+) common lymphoid progenitors expressing lymphoid-specific genes.

Hoebeke I, De Smedt M, Stolz F, Pike-Overzet K, Staal FJ, Plum J, Leclercq G. Hoebeke I, et al. Leukemia. 2007 Feb;21(2):311-9. doi: 10.1038/sj.leu.2404488. Epub 2006 Dec 14. Leukemia. 2007. PMID: 17170726

6

Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.

Pike-Overzet K, de Ridder D, Weerkamp F, Baert MR, Verstegen MM, Brugman MH, Howe SJ, Reinders MJ, Thrasher AJ, Wagemaker G, van Dongen JJ, Staal FJ. Pike-Overzet K, et al. Leukemia. 2007 Apr;21(4):754-63. doi: 10.1038/sj.leu.2404563. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268520

7

New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.

Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ. Pike-Overzet K, et al. Mol Ther. 2007 Nov;15(11):1910-6. doi: 10.1038/sj.mt.6300297. Epub 2007 Aug 28. Mol Ther. 2007. PMID: 17726455 Free article. Review.

8

Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?

Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. Staal FJ, et al. Leukemia. 2008 Oct;22(10):1849-52. doi: 10.1038/leu.2008.219. Epub 2008 Sep 4. Leukemia. 2008. PMID: 18769449 Review.

9

Isolation of human and mouse hematopoietic stem cells.

Ng YY, Baert MR, de Haas EF, Pike-Overzet K, Staal FJ. Ng YY, et al. Methods Mol Biol. 2009;506:13-21. doi: 10.1007/978-1-59745-409-4_2. Methods Mol Biol. 2009. PMID: 19110616

10

DNA microarray studies of hematopoietic subpopulations.

Pike-Overzet K, de Ridder D, Schonewille T, Staal FJ. Pike-Overzet K, et al. Methods Mol Biol. 2009;506:403-21. doi: 10.1007/978-1-59745-409-4_27. Methods Mol Biol. 2009. PMID: 19110641

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page